Keratan sulfate suppresses cartilage damage and ameliorates inflammation in an experimental mice arthritis model

Biochemical and Biophysical Research Communications

Volumn 401, Issue 3, 2010, Pages 463-468

  Hayashi, Masatoshi ^a   Kadomatsu, Kenji ^a   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Arthritis; Cartilage degradation; Keratan sulfate; Rheumatoid arthritis

Indexed keywords

AGGRECAN; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATAN SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; INFLAMMATORY DISEASE; KNEE RADIOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CARTILAGE; DISEASE MODELS, ANIMAL; INTERLEUKIN-17; KERATAN SULFATE; LYMPHOTOXIN-ALPHA; MICE; MICE, INBRED DBA; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 77958151838     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.082     Document Type: Article

References (40)

1. Paulos C.M., Turk M.J., Breur G.J., Low P.S. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Deliv. Rev. 2004, 56:1205-1217.
2. Lippiello L., Woodward J., Karpman R., Hammad T.A. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin. Orthop. Relat. Res. 2000, 381:229-240.
3. Kubo M., Ando K., Mimura T., Matsusue Y., Mori K. Chondroitin sulfate for the treatment of hip and knee osteoarthritis: current status and future trends. Life Sci. 2009, 85:477-483.
4. Tiraloche G., Girard C., Chouinard L., Sampalis J., Moquin L., Ionescu M., et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. 2005, 52:1118-1128.
5. Glant T.T., Buzas E.I., Finnegan A., Negroiu G., Cs-Szabo, Mikecz K. Critical roles of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation. J. Immunol. 1998, 160:3812-3819.
6. Venn G., Mason R.M. Absence of keratan sulphate from skeletal tissues of mouse and rat. Biochem. J. 1985, 228:443-450.
7. Mallinger R., Stockinger L. Histochemistry of the extracellular matrix of aging hyaline cartilage. Folia Histochem. Cytobiol. 1987, 25:129-132.
8. Venn M.F. Variation of chemical composition with age in human femoral head cartilage. Ann. Rheum. Dis. 1978, 37:168-174.
9. Asquith D.L., Miller A.M., McInnes I.B., Liew F.Y. Animal models of rheumatoid arthritis. Eur. J. Immunol. 2009, 39:2040-2044.
10. Majumdar M.K., Askew R., Schelling S., Stedman N., Blanchet T., Hopkins B., et al. Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis. Arthritis Rheum. 2007, 56:3670-3674.
11. Ghosh P., Shimmon S., Whitehouse M.W. Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy. Inflammopharmacology 2006, 14:155-162.
12. Leroux J.Y., Guerassimov A., Cartman A., Delaunay N., Webber C., Rosenberg L.C. Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. J. Clin. Invest. 1996, 97:621-632.
13. Boiers U., Lanig H., Sehnert B., Holmdahl R., Burkhardt H. Collagen type II is recognized by a pathogenic antibody through germline encoded structures. Eur. J. Immunol. 2008, 38:2784-2795.
14. Stanton H., Ung L., Fosang A.J. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem. J. 2002, 364:181-190.
15. Terato K., Harper D.S., Criffiths M.M., Hasty D.L., Ye X.J., Cremer M.A., et al. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995, 22:137-147.
16. Tanaka D., Kagari T., Doi H., Shimozato T. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 2006, 119:195-202.
17. Jochems C., Islander U., Kallkopf A., Lagerquist M., Ohlsson C., Carlsten H. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis Rheum. 2007, 56:3261-3270.
18. van den Berg W.B. Lessons from animal models of arthritis over the past decade. Arthritis Res. Ther. 2009, 11:250-251.
19. Joosten L.A., Helsen M.M., van de Loo F.A., van den Berg W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996, 39:797-809.
20. Campbell I.K., O'Donnell K., Lawlor K.E., Wicks I.P. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J. Clin. Invest. 2001, 107:1519-1527.
21. van den Berg W.B. What we learn from arthritis models to benefit arthritis patients. Baillieres Best Pract. Res. Clin. Rheumatol. 2000, 14:599-616.
22. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 2007, 56:2111-2115.
23. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007, 8:345-350.
24. Lubberts E., van den Bersselaar L., Oppers-Walgreen B., Schwarzenberger P., Coenen-de Roo C.J., Kolls J.K., Hoosten L.A., et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J. Immunol. 2003, 170:2655-2662.
25. Kagari T., Doi H., Shimozato T. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 2002, 169:1459-1466.
26. Miagkov A.V., Varley A.W., Munford R.S., Makarov S.S. Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints. J. Clin. Invest. 2002, 109:1223-1229.
27. Yoshimura A., Mori H., Ohishi M., Aki D., Hanada T. Negative regulation of cytokine signaling influences inflammation. Curr. Opin. Immunol. 2003, 15:704-708.
28. Behera A.K., Hildebrand E., Szafranski J., Hung H.-H., Grodzinsky A.J., Lafyatis R., et al. Role of aggrecanase 1 in Lyme arthritis. Arthritis Rheum. 2006, 54:3319-3329.
29. Westling J., Fosang J.F., Last K., Thompson V.P., Tomkinson K.N., Hebert T., et al. ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase site (Asn341-Phe342) in the aggrecan interglobular domain. J. Biol. Chem. 2002, 277:16059-16066.
30. Sandy J.D., Flannery C.R., Neame P.J., Lohmander S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J. Clin. Invest. 1992, 89:1512-1516.
31. Lohmander L.S., Neame P.J., Sandy J.D. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993, 36:1214-1222.
32. Lark M.W., Bayne E.K., Lohmander L.S. Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Acta Orthop. Scand. Suppl. 1995, 266:92-97.
33. van Meurs J., van Lent P., Stoop R., Holthuysen A., Singer I., Bayne E., et al. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum. 1999, 42:2074-2084.
34. Caterson B., Flannery C.R., Hughes C.E., Little C.B. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000, 19:333-344.
35. Sandy J.D. A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 2006, 14:95-100.
36. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.-L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
37. Stanton H., Rogerson F.M., East C.J., Golub S.B., Lawlor K.E., Meeker C.T., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005, 434:648-652.
38. Little C.B., Meeker C.T., Bolub S.B., Lawlor K.E., Farmer P.J., Smith S.M., et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Invest. 2007, 117:1627-1636.
39. Cho S.Y., Sim J.S., Jeong C.S., Chang S.Y., Choi D.W., Toida T., et al. Effects of low molecular weight chondroitin sulfate on type II collagen-induced arthritis in DBA/1J mice. Biol. Pharm. Bull. 2004, 27:47-51.
40. McGuigan C., Serpi M., Bibbo R., Roberts H., Hughes C., Caterson B., et al. Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery. J. Med. Chem. 2008, 51:5807-5812.